RecruitingNot ApplicableNCT07564375

MBA Early Feasibility Study

Early Feasibility Study of the GORE® Multibranch Arch Endoprosthesis (MBA Device)

Sponsor

W.L.Gore & Associates

Enrollment

20 participants

Start Date

Sep 2, 2026

Study Type

INTERVENTIONAL

Conditions

Thoracic Aortic Aneurysm Pseudoaneurysm Penetrating Aortic Ulcers (PAUs)thoracic aortic dissection

Summary

The MBA 25-04 study is a prospective, multicenter, non-randomized, single-arm, early feasibility study designed to assess the initial safety of the MBA device through five years following the index endovascular procedure.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called GORE® Ascending Stent Graft and a medical device called GORE® Multibranch Arch Endoprosthesis for people with penetrating aortic ulcers (paus), pseudoaneurysm, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEGORE® Multibranch Arch Endoprosthesis

Primary Investigational Device

DEVICEGORE® Ascending Stent Graft

Secondary Investigational Device

Locations(2)

University of Southern California

Los Angeles, California, United States

Baylor Research Institute

Plano, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07564375

Related Trials

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

NCT063770331 location

European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™

NCT076686874 locations